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Overview of Zika Virus Testing 
Current guidance for US laboratories testing for Zika virus infection (https://www.cdc.gov/zika/laboratories/lab-
guidance.html) recommends that testing be limited to specimens collected from patients meeting CDC’s clinical 
and/or epidemiologic criteria for testing (http://www.cdc.gov/zika/symptoms/index.html; 
http://www.cdc.gov/zika/hc-providers).1  Clinical signs and symptoms associated with Zika virus infection are 
discussed here: http://www.cdc.gov/zika/symptoms. Current Zika information and guidance is available on 
CDC’s Zika website at http://www.cdc.gov/zika. Information specific to laboratories is available at 
http://www.cdc.gov/zika/laboratories.  
Current information and guidance specific to Zika virus in Puerto Rico can be found on the Puerto Rico 
Department of Health website: http://www.salud.gov.pr/Sobre-tu-Salud/Pages/Condiciones/Zika.aspx.  
Multiple assays and sample types are often needed to establish a definitive laboratory diagnosis of Zika virus 
infection due to the temporal nature of biologic analytes in the infected person. Viral ribonucleic acid (RNA) is 
the first analyte that can be detected in an infected person in multiple specimen types. As the immune response 
develops, immunoglobulin M (IgM) titers rise in peripheral blood and the level of viral RNA generally declines. 
However, viral RNA may be detectable in some infected people for longer periods in certain specimen types. 
Nucleic acid testing (NAT) is most informative in the first 6 weeks after symptom onset. IgM antibodies are most 
likely to be detected in the first 12 weeks after symptom onset, but may persist longer.  
                                                          
1 The term “clinical and/or epidemiologic criteria” refers to factors such as symptoms, pregnancy, and exposure risk. Please 
refer to current CDC clinical guidance: http://www.cdc.gov/zika/hc-providers/index.html  
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Zika virus infection can cause signs and symptoms similar to those seen in patients with other arthropod-borne 
virus (arbovirus) infections, including dengue viruses, related flaviviruses, and chikungunya virus, an unrelated 
alphavirus. For differential diagnosis of Zika virus infection, testing for other circulating arboviruses/flaviviruses 
should be considered. A positive result for one of these viruses does not preclude infection with the others. Co-
infection with Zika virus and dengue or chikungunya viruses is rare, but possible, particularly in areas where 
these viruses are co-circulating. 
Paired serum and urine are the primary diagnostic specimens for Zika virus infection. Other specimen types 
such as plasma, whole blood, cerebrospinal fluid (CSF), and amniotic fluid are authorized for use with some 
assays that have received an Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA). 
For all diagnostic testing conducted on specimen types other than patient-matched serum and urine, it is 
necessary to concurrently obtain a patient-matched serum specimen for NAT and/or IgM (serology) testing, as 
appropriate. Please review assay instructions to determine acceptable specimen types for a given assay. 
Instructions for use of assays authorized for diagnostic use under an FDA EUA can be found under the “Labeling” 
bullet for each assay on the FDA website at: 
http://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika 
This updated guidance makes the following recommendations for Zika virus testing in:  
• Symptomatic pregnant women with possible exposure to Zika virus.  Areas with risk of exposure can be 
found at https://wwwnc.cdc.gov/travel/page/world-map-areas-with-zika.   
• Asymptomatic pregnant women with ongoing possible exposure to Zika virus   
• Pregnant women with possible exposure to Zika virus who have a fetus with prenatal ultrasound 
findings consistent with congenital Zika virus infection 
• Non-pregnant symptomatic individuals with possible exposure to areas with risk of Zika virus 
transmission 
Zika virus testing may be considered for: 
• Asymptomatic pregnant women with recent possible but no ongoing exposure to Zika virus (i.e., 
travelers). Although not routinely recommended, testing may be considered on a case-by case basis and 
in line with jurisdictional recommendations.  
Zika virus testing is not recommended for: 
• Non-pregnant asymptomatic individuals 
• Pre-conception screening 
 
 Laboratories should complete ALL specimen testing, including any indicated repeat testing, before 
reporting test results to provider.  Clinical decisions surrounding patient management should not be made 
until the appropriate testing algorithm is completed. 
Overview of Updates to Testing Guidance  
The Updated Interim Guidance for Healthcare Providers Caring for Pregnant Women with Possible Zika Virus 
Exposure – United States, July 2017 can be found at 
https://www.cdc.gov/mmwr/volumes/66/wr/mm6629e1.htm?s_cid=mm6629e1_w.  The interim guidance has 
July 24, 2017   Page 3 of 16 
 
been updated based on declining trends in the number of reported cases of Zika virus infection in Region of the 
Americas, emerging evidence on prolonged detection of Zika immunoglobulin M (IgM) antibodies, and new 
limitations for interpreting serologic tests during pregnancy. Although IgM is most likely to be detected in the 
first 12 weeks after infection, emerging data indicate that Zika virus IgM may persist beyond 12 weeks in a 
subset of infected individuals, limiting the ability of testing to determine whether an infection occurred during 
or prior to pregnancy. IgM tests are also susceptible to false positives and cross-reactivity with other flaviviruses, 
especially when an individual has been vaccinated against or previously infected with a related flavivirus.  In the 
United States, as the decline in reported Zika virus cases (including travel-associated cases) continues, the 
proportion of positive tests that are false positives for Zika virus are expected to increase due to a low positive 
predictive value. Key changes in the updated guidance for testing pregnant women have been made taking 
these testing limitations into consideration.  
Key updates to the guidance: 
1. Symptomatic pregnant women with possible Zika virus exposure should be tested. When testing 
symptomatic pregnant women, concurrent NAT and IgM testing is recommended as soon as possible, up to 
12 weeks after symptom onset.  The recommendation for Zika virus NAT testing has been expanded from ≤ 
2 weeks to ≤ 12 weeks because of evidence that Zika virus RNA may persist in the serum of pregnant women 
with Zika virus infection.  NAT testing is now recommended on paired serum AND urine specimens collected 
at the same visit.  
 
2. Asymptomatic pregnant women with ongoing possible exposure to Zika virus should be tested. NAT testing 
is recommended three times during pregnancy. IgM serology testing is not routinely recommended.  
Recommendations for the timing of NAT testing are at the initial prenatal care visit, followed by two 
additional NAT tests performed during pregnancy, coinciding with non-consecutive prenatal visits. Timing of 
additional NAT testing may be informed by jurisdictional trends in Zika virus transmission, the expected 
length of Zika virus nucleic acid detection in serum, and the duration of exposure during pregnancy.  
Although not routinely recommended, after pre-test counseling and individualized risk assessment, 
physicians and patients, through a shared decision-making model, may collaboratively elect to have IgM 
testing performed concurrent with NAT testing. For women who have a positive NAT test during pregnancy, 
additional NAT testing is not recommended.  If a patient has previously been confirmed positive for Zika 
virus infection, no additional IgM serology testing is recommended.   
 
3. Asymptomatic pregnant women with recent possible Zika virus exposure but no ongoing exposure (i.e., 
travelers) may be considered for testing. Although not routinely recommended, testing may be considered 
on a case-by-case basis using a shared physician-patient decision-making model and in line with 
jurisdictional recommendations. If testing of asymptomatic pregnant women is performed, the same 
algorithm as for symptomatic pregnant women should be followed using the timeframe from the last 
possible exposure to Zika virus.  
 
4. Pregnant women with possible exposure to Zika virus and who have a fetus with prenatal ultrasound 
findings consistent with congenital Zika virus infection should be tested. NAT and IgM testing should be 
performed on maternal serum and urine following the algorithm for symptomatic pregnant women.  If 
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amniocentesis is being performed as part of clinical care, NAT testing of amniocentesis specimens should 
also be performed. Testing of placental and fetal tissues may also be considered. 
Testing guidance for symptomatic non-pregnant individuals remains unchanged with this updated interim 
guidance. Pre-conception screening and baseline serum screening are not recommended. There are currently no 
EUA-approved tests for screening of semen for male partners requesting screening. 
 
Information regarding testing infants at the time of birth can be found at http://www.cdc.gov/zika/hc-
providers/test-specimens-at-time-of-birth.html and also in the Interim Guidance for the Evaluation and 




To ensure laboratory safety when working with Zika virus, please review CDC guidance on Transport and 
Handling of Diagnostic Specimens and Working with Zika Virus in the Laboratory: 
http://www.cdc.gov/zika/laboratories/lab-safety.html. See Biosafety in Microbiological and Biomedical 
Laboratories (BMBL) for additional biosafety information about arboviruses and laboratory biosafety practices: 
http://www.cdc.gov/biosafety/publications/bmbl5/index.htm. 
Testing Methods 
• Additional volume of serum beyond what is recommended in EUAs should be obtained in case 
repeated NAT testing is indicated by initial test results. 
• The updated interim guidance recommends that NAT and IgM serology testing be performed 
concurrently when testing symptomatic pregnant women.  
• The updated interim guidance recommends that NAT testing be performed concurrently on both 
serum AND a paired urine specimen when testing symptomatic pregnant women.  
• When the risk of exposure to Zika virus is low, the incidence of false positive test results is increased 
for both NAT and IgM serology testing. Further, IgM testing does not provide a clear determination of 
the timing of exposure, and a positive IgM result may represent recent or persistent IgM response to 
Zika virus or another flavivirus infection. 
• Given the possibility of a false positive result, laboratory test results should not be released until all 
testing is complete. 
• It is recommended that healthcare decisions not be made until testing according to the appropriate 
algorithm is complete. 
Molecular Testing 
Nucleic acid test, or NAT, is a generic term referring to all molecular tests used to detect viral genomic material.  
Despite the specificity of molecular testing, false positive NAT results have been reported in rare cases and may 
depend on the type of NAT assay performed and patient population (i.e., limited or no prevalence of viral 
transmission) being tested. This problem can be exacerbated when Zika virus testing is performed on patient 
populations not recommended in the Zika testing algorithms. Testing is not recommended for asymptomatic 
non-pregnant individuals, or for pre-conception screening for either the woman or her partner. 
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Under updated recommendations, repeat NAT testing of the same specimen beginning with a new extraction 
is recommended in some circumstances. To reduce the loss of detectable viral RNA in urine specimens, urine 
should only be stored at 4 ˚C for ≤ 48 hours, and any indicated repeat NAT testing of urine specimens should 
be performed within that time. 
The Updated Interim Guidance for Healthcare Providers Caring for Pregnant Women with Possible Zika Virus 
Exposure – United States, July 2017 can be found at 
https://www.cdc.gov/mmwr/volumes/66/wr/mm6629e1.htm?s_cid=mm6629e1_w.   
Updated recommendations for NAT testing of pregnant women are as follows:  
Symptomatic Pregnant Women 
For symptomatic pregnant women with possible exposure to Zika virus, NAT and IgM serology testing for Zika 
virus should be performed concurrently (i.e., in parallel) on specimens collected as soon as possible, up to 12 
weeks post-symptom onset. Patients should also be evaluated for other pathogens (including dengue virus) 
circulating in areas where they have traveled or lived. Possible exposure may include travel to or residence in 
areas with increased risk of Zika virus infection or unprotected sex with a partner who has traveled to or lives in 
an area with increased risk of Zika virus exposure. Areas with risk of exposure can be found at 
https://wwwnc.cdc.gov/travel/page/world-map-areas-with-zika.   
IgM antibodies usually become detectable within a week following symptom onset and decline over time, 
therefore a negative IgM assay result on a serum specimen collected less than 2 weeks before or more than 12 
weeks after symptom onset does not rule out a recent Zika virus infection. A positive NAT result with a 
concurrent negative IgM result on a specimen <14 days post symptom onset or most recent exposure may 
reflect specimen collection before the development of detectable antibodies or, in rare cases, a false positive 
assay result. Despite the specificity of NAT, false positive NAT results have been reported. If both serum and 
urine test positive for Zika virus, repeat NAT testing is not required (see Table 1). If NAT is only positive on 
serum or urine, and IgM antibody testing is negative, NAT should be repeated on the original, positive 
specimen beginning with a new extraction.  If the quantity of specimen is not sufficient for repeat NAT testing 
or if the original NAT is positive and repeat NAT is negative, IgM testing is recommended on a serum specimen 
collected ≥ 2 weeks after date of most recent specimen draw.  For women who are NAT positive during 
pregnancy, additional NAT testing is not recommended.  If more than 12 weeks have passed since symptom 
onset, IgM serology testing without NAT may be considered but a negative IgM result does not rule out recent 
infection. 
Asymptomatic Pregnant Women 
Testing is recommended for asymptomatic pregnant women with ongoing possible exposure to Zika virus. 
Ongoing exposure may include daily travel to or residence in areas with risk of Zika virus infection or 
unprotected sex with a partner who travels to or resides in an area with risk of Zika virus exposure. Areas with 
risk of exposure can be found at https://wwwnc.cdc.gov/travel/page/world-map-areas-with-zika.  NAT testing 
for evidence of Zika virus infection is recommended three times during pregnancy, but IgM serology testing is 
not routinely recommended.  Recommendations for the timing of NAT testing are at the initial prenatal care 
visit, followed by two additional NAT tests, the timing and frequency of which are at the discretion of the 
provider and dependent on the risk of exposure and the results of the initial NAT test. If the initial NAT test is 
positive, no additional NAT tests are recommended during pregnancy. While not routinely recommended, after 
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pre-test counseling, physicians and patients may elect to have IgM testing performed concurrently with NAT 
testing. For women who have a positive NAT result during pregnancy, additional NAT testing is not 
recommended. If a patient has previously been confirmed positive for Zika virus infection, no additional IgM 
serology testing is recommended. If both serum and urine test positive for Zika virus, repeat NAT testing is not 
required (see Table 1).   
Testing of asymptomatic pregnant women with recent possible Zika virus exposure but no ongoing exposure 
(i.e., travelers) should be considered on a case–by-case basis and in line with jurisdictional recommendations. If 
testing is conducted, the testing algorithm for symptomatic pregnant women should be followed, with 
specimens collected as soon as possible, not to exceed 12 weeks from the last possible exposure. 
Pregnant Women with Prenatal Ultrasound Findings Consistent with Congenital Zika Virus 
Infection 
Pregnant women with possible exposure to Zika virus who have a fetus with prenatal ultrasound findings 
consistent with congenital Zika virus infection should be tested.  Possible exposure may include travel to or 
residence in areas with risk of Zika virus infection or sex with a partner who has traveled to or lives in an area 
with risk of Zika virus exposure. Areas with risk of exposure can be found at 
https://wwwnc.cdc.gov/travel/page/world-map-areas-with-zika.  NAT and IgM testing should be performed on 
maternal serum and urine following the algorithm for symptomatic pregnant women.  If amniocentesis is being 
performed as part of clinical care, NAT testing of amniocentesis specimens should also be performed. Data 
regarding the utility of amniotic fluid in diagnosing congenital Zika virus infection are limited.   
Symptomatic Non-Pregnant Individuals 
NAT testing of symptomatic non-pregnant individuals is dependent on the timing of specimen collection. Zika 
virus and dengue virus NAT testing should be performed on specimens collected < 14 days after symptom onset 
(Figure 1). Zika virus and dengue virus IgM serology testing should be performed on NAT negative samples 
collected <14 days after onset of symptoms or on samples collected ≥ 14 days after onset of symptoms, and NAT 
testing is not recommended on specimens collected ≥ 14 days after symptom onset. NAT testing is not 
recommended for asymptomatic non-pregnant individuals. 
Additional Molecular Test Information 
Multiple NATs have received EUA) from FDA. Most, but not all, of the NATs that have received EUAs from FDA 
are rRT-PCR-based. FDA maintains a list on its website of all Zika virus EUAs. Please refer to the FDA website for 
a current list of authorized assays and associated letters of authorization, fact sheets, and product labeling. 
Additional assay-specific information (e.g., performance characteristics) is included in the labeling for the assay. 
http://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm.  
Information about molecular assays that have been cleared by FDA for detection of arboviruses other than Zika 
virus can be found in the searchable database at this link: 
http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/510kClear
ances/ucm089319.htm. 
Antibody Detection Methods 
Due to the temporal nature of Zika virus RNA in serum and urine, a negative NAT does not exclude recent Zika 
infection. Serologic detection of Zika virus infection may help confirm exposure to Zika virus in settings where 
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people have not previously been exposed to Zika virus. Antibodies (IgM) directed against Zika virus are typically 
first detected as viral RNA begins to wane. The decline in reported cases of Zika virus infection in the Americas in 
2017 compared to 2016 is expected to increase the proportion of false positive test results for Zika virus. 
Although IgM is most likely to be detected in the first 12 weeks after infection, emerging data indicate that Zika 
virus IgM may persist beyond 12 weeks in a subset of infected individuals, limiting the ability of testing to 
determine whether an infection occurred during or prior to pregnancy. These limitations are a particular 
challenge when Zika virus testing is performed on patient populations not recommended in the Zika testing 
algorithms.  Testing is not recommended for asymptomatic non-pregnant individuals or for pre-conception 
screening. The updated testing algorithms recommend serologic testing for the following patient populations: 
Pregnant Women 
For symptomatic pregnant women, NAT and IgM serology for Zika virus and dengue virus should be performed 
concurrently (i.e., in parallel) on specimens collected ≤ 12 weeks after symptom onset. IgM antibodies decline 
over time. Therefore, a negative IgM assay result does not rule out a recent Zika virus infection.  
For asymptomatic pregnant women, if testing is conducted, the same testing recommendation should be 
followed as for symptomatic pregnant women, on specimens collected ≤ 12 weeks from the last possible 
exposure to Zika virus. Testing for other arboviral pathogens is not routinely recommended for asymptomatic 
pregnant women.  
Non-Pregnant Symptomatic Individuals 
For non-pregnant symptomatic individuals, specimens collected from > 14 days to < 12 weeks after symptom 
onset should be tested using anti-Zika IgM and anti-dengue IgM as the recommended initial assay. IgM testing is 
not recommended for non-pregnant asymptomatic individuals (Figure 1). 
Additional Serologic Test Information 
For explanation of a specific interpretation on Zika virus IgM serology assays, refer to the instructions for use for 
the specific assay performed. Information on each assay can be found at 
https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika, under the “Labeling” 
bullet for the specific assay.  The Updated Interim Guidance for Healthcare Providers Caring for Pregnant 
Women with Possible Zika Virus Exposure – United States, July 2017 
(https://www.cdc.gov/mmwr/volumes/66/wr/mm6629e1.htm?s_cid=mm6629e1_w), contains specific 
information that guides the overall interpretation of combined results from Zika virus and dengue virus serology 
and PRNT. This information may also be found in Tables 1 and 2.  
Zika virus IgM assays give a presumptive positive result, and final assay interpretation depends on additional 
results from confirmatory testing, such as the plaque reduction neutralization test (PRNT).  Given the possibility 
of a false positive result, most likely due to cross reactivity, which has been reported, it is recommended that 
healthcare decisions are not made until the testing algorithm is complete.  PRNT testing is recommended for 
serum specimens that yield a non-negative IgM serology result. However, PRNT may also reflect prior infection, 
and cannot be used to determine the timing of Zika virus infection. Terminology indicating a non-negative IgM 
serology result varies by assay, and may include positive, equivocal, presumptive, or possible Zika virus results. 
Neutralizing antibodies develop shortly after IgM antibodies and likely persist for many years (22). Based on 
experience with other flaviviruses, previous Zika virus infection is likely to confer prolonged, possibly lifelong, 
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immunity (23). Testing is not routinely recommended for pregnant women who have been previously diagnosed 
with confirmed Zika virus infection by either NAT or serology (Zika IgM positive/equivocal and Zika PRNT ≥ 10 
and Dengue PRNT <10). However, for pregnant women without a previous definitive diagnosis of Zika virus 
infection (e.g., pregnant women with laboratory evidence of recent flavivirus infection or laboratory evidence of 
presumptive Zika or flavivirus infection), given the limitations of serology testing (e.g., cross-reactivity and false 
positive test results), decisions about testing during a subsequent pregnancy should be made using a shared 
patient-provider decision-making model. If the decision is made to test, only NAT testing is recommended, 
because IgM antibody test might not be able to determine the timing of infection among pregnant women who 
had exposure to Zika virus before the current pregnancy   
Zika and dengue viruses have similar clinical presentations, transmission cycles, and geographic distributions, 
and cross-reactivity on serologic assays for these viruses is common. Dengue IgM testing should be performed 
on any symptomatic person with possible dengue exposure so they can receive appropriate clinical 
management; dengue virus IgM testing is not recommended for asymptomatic pregnant women or 
asymptomatic non-pregnant individuals. Currently, for one FDA–authorized Zika IgM assay, follow-up testing is 
to be done with an FDA-cleared dengue IgM assay when the final interpretation is “Presumptive Other Flavivirus 
Positive” due to the inclusion of a cross-reactive control that includes a dengue virus antigen. For this same 
assay, follow-up testing is to be done with an FDA-cleared West Nile virus IgM assay when the final 
interpretation is “Presumptive Other Flavivirus Positive,” as the other component of the cross-reactive control is 
West Nile virus antigen. For people who were in regions with known endemic flavivirus activity (e.g., West Nile 
virus, St. Louis encephalitis virus) during their potential exposure period, IgM testing for those viral infections 
should be considered using an FDA-cleared assay, if available. For more information about West Nile virus, 
please access the following link: http://www.cdc.gov/westnile/index.html. Because infections with other 
arboviruses, including chikungunya virus, can also produce symptoms similar to Zika virus infection, additional 
testing for other arboviruses is often needed to reach a diagnosis. For people with chikungunya virus exposure 
risk and a clinically compatible illness2, anti-chikungunya IgM testing should also be performed.   
FDA maintains on its website a list of all Zika virus EUAs. Please refer to the FDA website for a current list of 
authorized assays and associated letters of authorization, fact sheets, and product labeling. Assay-specific 
information (e.g., performance characteristics) is included in the labeling for each assay.  
http://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm 
Confirmation of Anti-Zika IgM Reactive Results and Anti-Dengue IgM Reactive Results by Plaque Reduction 
Neutralization Test (PRNT) 
Zika virus IgM assays yield a presumptive positive result, and final assay interpretation depends on additional 
results from confirmatory testing, such as the PRNT.  PRNT measures virus-specific neutralizing antibodies to 
Zika virus and other endemic flaviviruses. Currently, within the United States and most US territories, when IgM 
serology indicates the potential presence of anti-Zika IgM antibodies, PRNT is needed to confirm diagnosis. If 
ELISA testing indicates a positive or equivocal result for dengue virus infection, confirmatory testing is to be 
performed as indicated in the IgM assay labeling.  PRNT is performed at CDC, a laboratory designated by the CDC 
(i.e., a laboratory that has independently demonstrated proficiency to perform PRNT testing by completing a 
                                                          
2 Clinical information about chikungunya virus infection, including clinical evaluation guidance, may be found on CDC’s 
website: www.cdc.gov/chikungunya/hc/index.html 
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proficiency panel provided by the CDC), or a public health laboratory (PHL) PRNT reference center. Confirmatory 
testing can take up to 4 weeks, and PRNT results will be reported via the laboratory to which the original 
specimen was submitted. 
Given the high degree of antibody cross-reactivity observed with Zika virus and dengue virus infections, results 
of Zika/dengue PRNT testing should be interpreted alongside the initial IgM assay results to assess the timing of 
infection. PRNT is not always able to provide a definitive determination of the specific flavivirus causing a recent 
infection, particularly in people with a prior history of flavivirus infection.  For this reason, PRNT confirmation is 
not routinely recommended for people living in areas with high levels of circulating flaviviruses (e.g., dengue).  
The Updated Interim Guidance for Healthcare Providers Caring for Pregnant Women with Possible Zika Virus 
Exposure – United States, July 2017 
(https://www.cdc.gov/mmwr/volumes/66/wr/mm6629e1.htm?s_cid=mm6629e1_w) and Tables 1 and 2 below 
contain specific information that guides the overall interpretation of combined results from Zika virus and 
dengue virus serology and PRNT. 
For additional information, please refer to CDC guidance on clinical management of patients with positive assay 
results: http://www.cdc.gov/zika/hc-providers/index.html.   
Detailed Information for Specimen Types for Zika Testing 
Detailed characteristics of the various specimen types that have been validated for use with Zika virus diagnostic 
assays can be found at http://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm and 
at https://www.cdc.gov/zika/laboratories/test-specimens-bodyfluids.html.  Individual FDA-authorized assays 
have specific information concerning specimen handling and storage. It is important to note that all diagnostic 
algorithms for pregnant women are for patient-matched serum and urine, and a patient-matched serum 
specimen must be submitted alongside all other sample types for follow-up testing, if needed.  Consider 
collecting additional volume beyond what is suggested in EUAs, to permit for potential repeat specimen 
testing. 
Tissue Specimens 
There are currently no FDA-authorized assays for Zika virus testing of tissue specimens, including fetal and 
placental tissue. Requests for testing should be coordinated through state or local health departments and pre-
approval is required before submission to CDC. Additional information about specimen collection and 
submission procedures is available on CDC’s website:  https://www.cdc.gov/zika/laboratories/test-specimens-
tissues.html. 
Other Specimens Types 
There are currently no FDA-authorized Zika virus assays for which performance with other specimen types, such 
as semen and saliva, has been established. 
Specimen Referral 
Healthcare and laboratory professionals should direct Zika virus testing requests to their local or state public 
health laboratory or to a commercial laboratory that performs Zika virus testing using an FDA-authorized assay. 
Healthcare and laboratory professionals should follow state or local public health department guidance on 
notification procedures for suspect cases of Zika virus infection. 
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Public health laboratories that do not perform Zika virus testing should work with their state, local, or territorial 
public health department for testing of suspect specimens or referring specimens to CDC.   
When submitting specimens for Zika virus testing, indicate pregnancy status and exposure risk of patient to 
ensure appropriate testing algorithm is followed. 
Information regarding submission of specimens to CDC from locations within the 50 US states and the District of 
Columbia is available at http://www.cdc.gov/ncezid/dvbd/specimensub/arboviral-shipping.html.   
For questions about testing within Puerto Rico, please call 787-706-2399. For submission of specimens, please 
submit a dengue case investigation report (DCIR) for each specimen, which can be downloaded from 
http://www.cdc.gov/dengue/clinicalLab/index.html. 
Reporting 
Clinical decisions surrounding patient management should not be made until the appropriate testing, according 
to the most recent algorithm, is completed.  Recommended testing may include repeated NAT testing, serology, 
and PRNT testing, thus providers may receive multiple NAT and serology test reports from more than one 
testing laboratory before all testing of a patient specimen is completed. Further, jurisdictional testing may vary 
from CDC recommended guidelines. For guidance on final result interpretation, healthcare providers should 
consult with their local jurisdiction. 
Laboratories should complete specimen testing, including any indicated repeat testing, before submitting test 
results to providers. Assay results generated for each specimen should be reported to clinicians as specified in 
the assay instructions for use. Reports should include language indicating that clinical decisions surrounding 
patient management should not be made until all testing is complete and should be considered within the 
context of all test results, and clinical and epidemiologic criteria as specified for the testing algorithm 
appropriate for the person being tested. 
Laboratories must include the appropriate fact sheets with each FDA-authorized test result when reporting back 
to providers and patients. Fact sheets have been prepared for healthcare providers and patients to help them 
understand the results of testing. Authorized fact sheets for each assay under an EUA are posted to the FDA 
website: http://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm 
In addition, laboratories must collect information on the performance of any of the EUA Zika assays and report 
to FDA (via email: CDRH-EUA-Reporting@fda.hhs.gov) and the assay manufacturer any occurrence of false 
positive or false negative results of which they become aware. 
Please note that Zika, dengue, West Nile, and chikungunya virus infections are all on the 2017 list of nationally 
notifiable conditions: https://wwwn.cdc.gov/nndss/conditions/notifiable/2017/. Therefore, test results should 
be reported back to state or local health department staff to facilitate investigation and classification of the case 
and reporting to CDC. 
Guidance documents are available to assist in applying laboratory results to determine patient care and patient 
follow-up decisions:  
• Zika clinical guidance for healthcare providers caring for pregnant women, women of reproductive age, 
infants, children, or other symptomatic individuals: http://www.cdc.gov/zika/hc-providers/index.html 
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• Dengue clinical guidance: http://www.cdc.gov/dengue/clinicalLab/index.html 
• Chikungunya clinical guidance: http://www.cdc.gov/chikungunya/hc/index.html 
• West Nile clinical guidance: https://www.cdc.gov/westnile/healthcareproviders/index.html 
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Table 1. Interpretation of results of nucleic acid and antibody testing for suspected Zika virus infection*,†, §, ¶— 





Zika virus and 
dengue virus IgM†† 
Zika virus PRNT Dengue virus 
PRNT 
Interpretation and recommendations 
Positive Positive Any result   Not indicated Not indicated Acute Zika virus infection 
Negative Positive  Positive  Not indicated Not indicated Acute Zika virus infection 
Negative Positive Negative  Not indicated Not indicated Suggests acute Zika virus infection 
Repeat testing on original urine specimen.  
If repeat NAT result is positive, interpret as evidence 
of acute Zika virus infection 
If repeat NAT result is negative, repeat Zika virus 
IgM antibody testing on a serum specimen collected 
≥2 weeks after onset or possible exposure or 
specimen collection date.  
If repeat IgM antibody result is positive, interpret 
as evidence of acute Zika virus infection. 
If repeat IgM result is not positive, interpret as no 
evidence of Zika virus infection. 
Positive  Negative or 
not 
performed 
Positive  Not indicated Not indicated Acute Zika virus infection 
Positive  Negative or 
not 
performed  
Negative  Not indicated Not indicated Suggests Acute Zika virus infection 
Repeat testing on original serum specimen.  
If repeat NAT result is positive, interpret as evidence 
of acute Zika virus infection. 
If repeat NAT result is negative, repeat Zika virus 
IgM antibody testing on a serum specimen collected 
≥2 weeks after onset or possible exposure or 
specimen collection date.  
If repeat IgM antibody result is positive, interpret 
as evidence of acute Zika virus infection. 
If repeat IgM antibody result is not positive, 
interpret as no evidence of Zika virus infection. 





≥10 <10 Zika virus infection, timing of infection cannot be 
determined. For persons without prior Zika virus 
exposure, a positive IgM result represents recent Zika 
virus infection. 





<10 Any result No evidence of Zika virus infection. 





≥10 ≥10 Flavivirus infection; specific virus cannot be identified, 
timing of infection cannot be determined. For persons 
without prior Zika virus exposure, a positive IgM result 
represents unspecified flavivirus infection. 
For areas where PRNT is not recommended¶ 
Negative  Negative or 
not 
performed 
Positive for Zika 
virus AND negative 
for dengue virus 
Not performed because PRNT is 
not recommended  
Presumptive Zika virus infection; timing of infection 
cannot be determined.*** 
  
Negative  Negative or 
not 
performed 
Positive for Zika 
virus AND positive 
for dengue virus 
Not performed because PRNT is 
not recommended  
Presumptive flavivirus infection; specific virus cannot be 
identified; timing of infection cannot be 
determined.***  
Negative  Negative or 
not 
performed 
Equivocal (either or 
both assays) 
Not performed because PRNT is 
not recommended  
Insufficient information for interpretation. Consider 
repeat testing. 






Zika virus and 
dengue virus IgM†† 
Zika virus PRNT Dengue virus 
PRNT 
Interpretation and recommendations 
Negative Negative or 
not 
performed 
Negative on both 
assays 
Not performed because PRNT is 
not recommended in certain area 
of residence (i.e. Puerto Rico) 
No laboratory evidence of Zika virus infection. 
 
Abbreviations: IgM = immunoglobulin M antibodies; NAT= nucleic acid test; PRNT = plaque reduction 
neutralization test. 
* Final interpretations of results of Zika virus tests should be performed after all testing is complete. 
† Serology test results that indicate recent flavivirus infection should be interpreted in the context of the 
circulating flaviviruses. 
§ Dengue virus IgM antibody testing is recommended for symptomatic pregnant women as well as for pregnant 
women residing in areas where PRNT confirmation is not recommended. 
¶ Currently, PRNT confirmation is not routinely recommended for persons living in Puerto Rico. 
** Serum must be submitted for all persons tested for Zika virus infection; urine specimen for Zika virus NAT 
testing should always be submitted concurrently with a serum specimen. 
†† For laboratory interpretation in the presence of dengue virus IgM results, refer to 
https://www.cdc.gov/dengue/clinicallab/laboratory.html.  
§§ Positive results include “positive,” “presumptive Zika virus positive,” or “possible Zika virus positive.” These 
are examples of assay interpretations that might accompany test results; positive serology terminology varied by 
assay. For explanation of a specific interpretation, refer to the instructions for use for the specific assay 
performed. Information on each assay can be found at 
https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika under the “Labeling” 
bullet for the specific assay. 
¶¶ Non-negative results include “positive,” “equivocal,” “presumptive positive,” or “possible positive.” These are 
examples of assay interpretation that might accompany test results; nonnegative serology terminology varies by 
assay. For explanation of a specific interpretation, refer to the instructions for use for the specific assay 
performed. Information on each assay can be found at 
https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika under “Labeling” for 
the specific assay. 
*** Zika virus IgM positive result is reported as “presumptive positive or flavivirus infection” to denote the need 
to perform confirmatory PRNT titers against Zika virus, dengue virus, and other flaviviruses to which the person 
might have been exposed, to resolve potential false-positive results that might have been caused by cross-
reactivity or nonspecific reactivity. In addition, ambiguous test results (e.g., inconclusive, equivocal, and 
indeterminate) that are not resolved by retesting also should have PRNT titers performed to rule out a false-
positive result. However, PRNT confirmation is currently not routinely recommended for persons living in Puerto 
Rico.  
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Table 2. Interpretation of results of nucleic acid and antibody testing for suspected Zika virus infection in non-
pregnant individuals*,†, §, ¶, **,†† — United States, 2017 










Lab results should not be released until 
testing is complete 
Positive Positive Not indicated Not indicated 
 
Acute Zika virus infection. 
Positive Negative Not indicated Not indicated 
 




Positive Not indicated Not indicated 
 




Negative Negative Not indicated No laboratory evidence of Zika virus 
infection.  










≥10 <10 Zika virus infection, timing of infection 
cannot be determined. A positive IgM 
and PRNT result for Zika and a negative 
PRNT for dengue likely represents 


















≥10 ≥10 Flavivirus infection; specific virus cannot 
be identified, precise timing of infection 









Pending Presumptive Zika virus infection; timing 
of infection cannot be determined. For 
patients with no exposure prior to 
testing, a positive IgM result represents 
recent Zika infection.  However, without 
PRNT confirmatory testing, false 
positives cannot be ruled out. 
 
Abbreviations: IgM = immunoglobulin M antibodies; NAT= nucleic acid test; PRNT = plaque reduction 
neutralization test. 
* Serology test results that indicate recent flavivirus infection should be interpreted in the context of the 
currently circulating flaviviruses.  
† Examples of assay interpretations that are positive include positive, or presumptive Zika virus positive, or 
possible Zika virus positive. For explanation of a specific interpretation, refer to the instructions for use for the 
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specific assay performed. Information on each assay can be found at 
https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika, under the “Labeling” 
bullet for the specific assay. 
§ Serum must be submitted for all persons tested for Zika virus infection; urine specimen for Zika virus testing 
should always be submitted with a paired serum specimen.   
¶Zika virus IgM positive result is reported as “presumptive positive” to denote the need to perform confirmatory 
PRNT.  
**Currently, PRNT confirmation is not routinely recommended for individuals living in Puerto Rico.  
††To resolve false-positive results that might be caused by cross-reactivity or nonspecific reactivity, presumptive 
positive Zika virus IgM results should be confirmed with PRNT titers against Zika virus, dengue virus, and other 
flaviviruses to which the person might have been exposed. In addition, ambiguous test results (e.g., inconclusive, 
equivocal, and indeterminate) that are not resolved by retesting also should have PRNT titers performed to rule 
out a false-positive result. 
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Figure 1. Testing Recommendations for Symptomatic Non-Pregnant Individuals with Exposure to Zika Virus 
 
1NAT testing is not recommended for specimens obtained ≥ 14 days post-symptom onset. 
2Acceptable specimens for NAT testing include serum, or patient-matched serum and urine.  Repeat NAT testing 
of a positive result is not indicated.  Dengue and chikungunya virus NAT testing should be performed for patients 
at risk of exposure and with clinically compatible illness. 
3Dengue IgM serology should also be performed for patients at risk of exposure, and with clinically compatible 
illness. 
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symptom onset 
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symptom onset1 
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